12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Northera droxidopa regulatory update

Chelsea said it plans to modify the ongoing Phase III Study 306B trial of Northera droxidopa based on a meeting with FDA about a complete response letter for the neurogenic orthostatic hypotension (NOH) product. The company, which received the letter in March, hopes to resubmit an NDA in 1Q13.


Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >